HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


DOI: https://doi.org/10.29296/25877305-2020-07-02

E. Burygina; Y. Kozlova, Candidate of Medical Sciences; Professor N. Klimko, MD North-Western
State Medical University named after I.I. Mechnikov, Saint Petersburg

Chronic spontaneous urticaria (CSU) – is a disease associated with degranulation of mast cells and appearing of weals and/or angioedema during more than 6 weeks without specific trigger. Medical and social significance of CSU is connected with its wide distribution mostly among able-bodied population, significant life quality impairment and high treatment costs. Immune and pathogenetical mechanisms of CSU development can vary significantly among patients. Actual task of the modern medicine is a search for new clinical and laboratory markers of CSU which can help to determine better treatment approach, changes in disease activity and to predict treatment response.

chronic spontaneous urticaria
treatment efficiency

  1. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/EDF/ WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73: 1393–414. DOI: 10.1111/all.13397
  2. Danilycheva I.V. Novyj evropejskij soglasitel'nyj dokument po diagnostike i vedeniju hronicheskoj krapivnitsy. Chto novogo? Rossijskij allergologicheskij zhurnal. 2018; 15 (4): 54–61 [Danilycheva I.V. New European urticaria guideline. What’s new? Russian Allergology Journal. 2018; 15 (4): 54–61 (in Russ)].
  3. Lee N., Lee J.D., Lee H.Y. et al. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010–2014. Allergy Asthma Immunol Res. 2017; 9 (5): 438–45. DOI: 10.4168/aair.2017.9.5.438
  4. Colgecen E., Kemal O., Gul A.I. et al. Evaluation of Etiological Factors in Patients with Chronic Urticaria. Acta Dermatovenerol Croat. 2015; 23 (1): 36–42.
  5. Kolkhir P., Church M.K., Weller K. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017; 139: 1772–81.e1. DOI: 10.1016/j.jaci.2016.08.050
  6. Curto-Barredo L., Archilla L.R., Vives G.R. et al. Clinical Features of Chronic Spontaneous Urticaria that Predict Disease Prognosis and Refractoriness to Standard Treatment. Acta Derm Venereol. 2018; 98 (7): 641–7. DOI: 10.2340/00015555-2941
  7. Schmetzer O., Lakin E., Topal F.A. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018; 142: 876–82. DOI: 10.10 16/j.jaci.2017.10.035
  8. Puxeddu I., Petrelli F., Angelotti F. et al. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications. J Asthma Allergy. 2019; 12: 285–95. DOI: 10.2147/JAA.S184986
  9. Stull D., McBride D., Tian H. et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017; 177: 1093–101. DOI: 10.1111/bjd.15454
  10. Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatology Venereol. 2017; 31 (6): 964–97. DOI: 10.1111/jdv.14221
  11. Amsler E., Augey F., Soria A.et al. Chronic urticaria and hormones: is there a link? J Eur Acad Dermatol Venereol. 2016; 30 (9): 1527–30. DOI: 10.1111/jdv.13644
  12. Hiragun M., Hiragun T., Mihara S. et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy Eur J Allergy Clin Immunol. 2013; 68 (2): 229–35. DOI: 10.1111/all.12078
  13. Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015; 29 (4): 698–701. DOI: 10.1111/jdv.12658
  14. Sánchez-Borges M., Tassinari S., Flores A. Epidemiologic features in patients with antihistamine-resistant chronic urticaria. Rev Alerg Mex. 2015; 62 (4): 279–86.
  15. Metz M., Giménez-Arnau A., Borzova E. et al. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Allergy Clin Immunol. 2009; 123: 705–6. DOI: 10.1016/j.jaci.2008.11.040
  16. Mosquera L., Milena K., Moya Camacho B. et al. The Autologous Serum Skin Test as a Prognostic Factor for the Severity and Duration of Chronic Urticaria after five years of Follow-up. J Allergy Clin Immunol. 2018; 141 (2): AB46.
  17. Grattan C., Dawn G., Gibbs S. et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003; 33: 337–41. DOI: 10.1046/j.1365-2222.2003.01589.x
  18. Kolkhir P., Church M.K., Altrichter S. et al. Eosinopenia in Chronic Spontaneous Urticaria Is Associated with High Disease Activity, Autoimmunity and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020; 8 (1): 318–25.e5. DOI: 10.1016/j.jaip.2019.08.025
  19. Rorsman H. Basopenia in urticaria. Acta Allergol. 1961; 16: 185–215. DOI: 10.1111/j.1398-9995.1961.tb02894.x
  20. Rauber M.M., Pickert J., Holiangu L. et al. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy. 2017; 72: 1904–11. DOI: 10.1111/all.13215
  21. Magen E., Mishal J., Zeldin Y. et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010; 339: 504–8. DOI: 10.1097/MAJ.0b013e3181db6ed5
  22. Kolkhir P., André F., Church M.K. et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017; 47: 19–36. DOI: 10.1111/cea.12870
  23. Tedeschi A., Asero R., Lorini M. et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy. 2010; 40: 875–81. DOI: 10.1111/j.1365-2222.2010.03473.x
  24. Kolkhir P., Altrichter S., Hawro T. et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73 (4): 940–8. DOI: 10.1111/all.13352
  25. Asero R. Severe CSU and activation of the coagulation/fibrinolysis system: clinical aspects. Eur Ann Allergy Clin Immunol. 2019; 52 (1): 15–7. DOI: 10.23822/EurAnnACI.1764-1489.109
  26. Kasperska-Zajac A., Grzanka A., Damasiewicz-Bodzek A. IL-6 transsignaling in patients with chronic spontaneous urticaria. PLoS One. 2015; 10 (12): e0145751. DOI: 10.1371/journal.pone.0145751
  27. Puxeddu I., Italiani P., Giungato P. et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine. 2013; 61 (3): 741–3. DOI: 10.1016/j.cyto.2013.01.015
  28. Atwa M.A., Emara A.S., Youssef N. et al. Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014; 28 (4): 469–74. DOI: 10.1111/jdv.12124
  29. Raap U., Wieczorek D., Gehring M. et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol. 2010; 19 (5): 464–6. DOI: 10.1111/j.1600-0625.2010.01067.x
  30. Bae Y., Kang S.H., Park J.O. et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int. 2019; 69 (2): 304–6. DOI: 10.1016/j.alit.2019.10.009 [Online ahead of print]
  31. Ye Y.M., Yang E.M., Yoo H.S. et al. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci. 2014; 29: 43. DOI: 10.3346/jkms.2014.29.1.43
  32. Woo Y.R., Jung K.E., Koo D.W. et al. Vitamin D as a marker for disease severity in chronic urticaria and its possible role in pathogenesis. Ann Dermatol. 2015; 27: 423. DOI: 10.5021/ad.2015.27.4.423
  33. Trinh H.K.T., Le P.D., Ban G.Y. et al. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016; 171 (2): 102–10. DOI: 10.1159/000452626
  34. Huilan Z., Bihua L., Runxiang L. et al. Features of antihistamine-resistant chronic urticaria and chronic urticaria during exacerbation. Indian J Dermatol. 2015; 60: 323. DOI: 10.4103/0019-5154.156458
  35. Bèlot V., Desbois I., Martin L. et al. Assessment of the usefulness of autologous serum skin testing in chronic urticaria: A retrospective single-centre study of 74 patients. Ann Dermatol Venereol. 2010; 137: 444–50. DOI: 10.1016/j.annder.2010.04.014
  36. Kolkhir P., Pogorelov D., Olisova O. CRP, D-Dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017; 49 (4): 189–92. DOI: 10.23822/EurAnnACI.1764-1489.05
  37. Gericke J., Metz M., Ohanyan T. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529-30. DOI: 10.1016/j.jaci.2016.07.047
  38. Straesser M.D., Oliver E., Palacios T. et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018; 6: 1386–8. DOI: 10.1016/j.jaip.2017.10.030
  39. Weller K., Ohanyan T., Hawro T. et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy Eur J Allergy Clin Immunol. 2018; 73: 2406–8. DOI: 10.1111/all.13586
  40. Asero R., Marzano A.V., Ferrucci S. et al. D-Dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017; 172: 40–4. DOI: 10.1159/000453453
  41. Altrichter S., Hawro T., Hänel K. et al. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatology Venereol. 2016; 30 (3): 454–5. DOI:10.1111/jdv.12831
  42. Deza G., Bertolin-Colilla M., Pujol R.M. et al. Basophil FcεR1 expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017; 97: 698–704. DOI: 10.2340/00015555-2654
  43. Metz M., Staubach P., Bauer A. et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017; 7: 1266–76. DOI: 10.7150/thno.18304
  44. Palacios T., Stillman L., Borish L. et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529–30. DOI: 10.1016/j.jaip.2015.11.025
  45. Ertaş R., Hawro T., Altrichter S. et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2019; 75 (2): 468–70. DOI: 10.1111/all.14033. [Online ahead of print]
  46. Kulthanan K., Subchookul C., Hunnangkul S. et al. Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review. Allergy Asthma Immunol Res. 2019; 11 (5): 736–55. DOI: 10.4168/aair.2019.11.5.736
  47. Iqbal K., Bhargava K., Skov P.S. et al. A positive serum basophil histamine release assay is a marker for cyclosporine responsiveness in patients with chronic spontaneous urticarial. Clin Transl Allergy. 2012; 2: 19. DOI: 10.1186/2045-7022-2-19
  48. Baek Y.S., Jeon J., Kim J.H. et al. Severity of acute and chronic urticaria correlates with D-dimer level, but not C-reactive protein or total IgE. Clin Exp Dermatol. 2014; 39: 795–800. DOI: 10.1111/ced.12413
  49. Asero R. Plasma D-dimer levels and clinical response to cyclosporine in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015; 135: 1401–3. DOI: 10.1016/j.jaci.2014.11.016
  50. Santiago L., Ferreira B., Ramos L. et al. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria. Br J Dermatol. 2019; 180: 199–200. DOI: 10.1111/bjd.17005